/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We develop, manufacture, and distribute products and provide services primarily for the companion animal veterinary; livestock, poultry and dairy; and water testing industries. Our primary products and services are: Point-of-care veterinary diagnostic products, comprised of instruments, consumables, and rapid assay test kits; Veterinary reference laboratory diagnostic and consulting services; P…
$584.68
$3.41 (-0.58%)
Live · 06:29 PM
Margins and capital returns are both well above average: 31.66% operating margin, ROIC at 48.51%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 10.4% YoY with margins expanding 2.7pp.
At 41x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
41.1x earnings, 37.0x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$4.54B
▲ +10.4% YoY
Net Income (TTM)
$1.14B
▲ +19.3% YoY
Op. Margin
32.11%
▲ +2.7pp YoY
ROIC
53.82%
▲ +9.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$1.25B
▲ +30.8% YoY
Op. Cash Flow (TTM)
$1.37B
▲ +27.2% YoY
Net Debt
$380M
Cash & Equiv.
$197M
5Y CAGR: +9.7%
5Y CAGR: +14.3%
Continue Research
SourceComputed from the 10-Q filed 4 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 5 Aug 2026. How this is calculated.
Price from market data, live as of 5 Aug 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 41.1 and a price-to-free-cash-flow of 37.0, IDEXX Laboratories (IDXX) trades above a two-stage DCF intrinsic value of about $574.74 per share, so at $584.68 the stock looks overvalued (1.7% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, IDEXX Laboratories scores 80/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $574.74 per share for IDXX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $431.05. At today's $584.68, that puts the stock about 1.7% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
IDEXX Laboratories scores 80 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a high-quality business on these measures. Recent fundamentals include a 32.1% operating margin and a 53.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. IDXX currently trades above its estimated intrinsic value and scores 80/100 on quality (high-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.